MedTrace Logo

Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection

NCT03205696 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2025-03-25

No results posted yet for this study

Summary

This is a strategic prospective cohort study which will measure the effects of early intensive antiretroviral therapy (ART) on the establishment and persistence of HIV-1 reservoirs and HIV-1-specific immunity in acutely /recently HIV infected youth aged 12 to 24 years as compared to newly diagnosed youth with established infection \> 6 months. Participants with newly diagnosed acute /recent HIV-1 infection will be offered enrollment into the study with immediate initiation of ART which is the current standard of care.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

Antiretrovirals

The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults

Sponsors & Collaborators

Principal Investigators

  • Karin Nielsen, M.D. · University of California, Los Angeles

Eligibility

Min Age
12 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2021-07-20
Completion
2023-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03205696 on ClinicalTrials.gov